Last updated: 18 June 2019 at 5:07am EST

Curtis Ruegg Net Worth




The estimated Net Worth of Curtis Ruegg is at least $205 Thousand dollars as of 13 June 2016. Curtis Ruegg owns over 1,000 units of Revance Therapeutics Inc stock worth over $164,132 and over the last 10 years Curtis sold RVNC stock worth over $41,100.

Curtis Ruegg RVNC stock SEC Form 4 insiders trading

Curtis has made over 27 trades of the Revance Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Curtis exercised 1,000 units of RVNC stock worth $8,700 on 13 June 2016.

The largest trade Curtis's ever made was exercising 3,000 units of Revance Therapeutics Inc stock on 17 August 2015 worth over $26,100. On average, Curtis trades about 1,029 units every 18 days since 2014. As of 13 June 2016 Curtis still owns at least 24,944 units of Revance Therapeutics Inc stock.

You can see the complete history of Curtis Ruegg stock trades at the bottom of the page.



What's Curtis Ruegg's mailing address?

Curtis's mailing address filed with the SEC is C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK, CA, 94560.

Insiders trading at Revance Therapeutics Inc

Over the last 11 years, insiders at Revance Therapeutics Inc have traded over $29,070,398 worth of Revance Therapeutics Inc stock and bought 136,530 units worth $2,014,047 . The most active insiders traders include Vlad Coric, Julian S Gangolli, and Angus C. Russell. On average, Revance Therapeutics Inc executives and independent directors trade stock every 31 days with the average trade being worth of $83,132. The most recent stock trade was executed by Erica Jordan on 16 April 2024, trading 2,392 units of RVNC stock currently worth $9,090.



What does Revance Therapeutics Inc do?

revance therapeutics, inc. is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. the company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented transmts® peptide delivery system to address unmet needs in the $3 billion neurotoxin market. revance's proprietary transmts technology enables delivery of botulinum toxin a through two novel dose formulations, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a more targeted and potentially longer lasting delivery. revance is currently pursuing clinical development for two product candidates, topical rt001 and injectable rt002, in a broad spectrum of aesthetic and therapeutic indications. rt001 is a topical gel, which has the potential to be the first commercially available non-injectable dose form



What does Revance Therapeutics Inc's logo look like?

Revance Therapeutics Inc logo

Complete history of Curtis Ruegg stock trades at Revance Therapeutics Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
13 Jun 2016 Curtis Ruegg
EVP and Technical Operations
Option 1,000 $8.70 $8,700
13 Jun 2016
24,944
9 May 2016 Curtis Ruegg
EVP and Technical Operations
Option 1,000 $8.70 $8,700
9 May 2016
26,264
11 Apr 2016 Curtis Ruegg
EVP and Technical Operations
Option 1,000 $8.70 $8,700
11 Apr 2016
26,264
11 Apr 2016 Curtis Ruegg
EVP and Technical Operations
Option 1,000 $8.70 $8,700
11 Apr 2016
26,264
7 Mar 2016 Curtis Ruegg
EVP and Technical Operations
Option 1,000 $8.70 $8,700
7 Mar 2016
26,264
7 Mar 2016 Curtis Ruegg
EVP and Technical Operations
Option 1,000 $8.70 $8,700
7 Mar 2016
26,264
8 Feb 2016 Curtis Ruegg
EVP and Technical Operations
Option 1,000 $8.70 $8,700
8 Feb 2016
18,264
8 Feb 2016 Curtis Ruegg
EVP and Technical Operations
Option 1,000 $8.70 $8,700
8 Feb 2016
18,264
6 Jan 2016 Curtis Ruegg
EVP and Technical Operations
Option 2,000 $8.70 $17,400
6 Jan 2016
20,027
17 Aug 2015 Curtis Ruegg
EVP and Technical Operations
Option 3,000 $8.70 $26,100
17 Aug 2015
21,027
17 Jul 2015 Curtis Ruegg
EVP and Technical Operations
Option 3,000 $7.41 $22,230
17 Jul 2015
21,027
17 Jun 2015 Curtis Ruegg
EVP and Technical Operations
Option 3,000 $6.60 $19,800
17 Jun 2015
21,027
3 Jun 2015 Curtis Ruegg
EVP and Technical Operations
Option 500 $6.60 $3,300
3 Jun 2015
18,527
15 May 2015 Curtis Ruegg
EVP and Technical Operations
Option 3,000 $6.60 $19,800
15 May 2015
21,837
17 Apr 2015 Curtis Ruegg
EVP and Technical Operations
Option 2,000 $6.60 $13,200
17 Apr 2015
20,337
19 Mar 2015 Curtis Ruegg
EVP and Technical Operations
Option 500 $6.60 $3,300
19 Mar 2015
19,837
17 Mar 2015 Curtis Ruegg
EVP and Technical Operations
Option 1,500 $6.60 $9,900
17 Mar 2015
20,837
9 Mar 2015 Curtis Ruegg
EVP and Technical Operations
Option 500 $6.60 $3,300
9 Mar 2015
19,837
17 Feb 2015 Curtis Ruegg
EVP and Technical Operations
Option 1,000 $5.91 $5,910
17 Feb 2015
20,337
20 Jan 2015 Curtis Ruegg
EVP and Technical Operations
Option 1,000 $2.55 $2,550
20 Jan 2015
15,106
9 Jan 2015 Curtis Ruegg
EVP and Technical Operations
Option 500 $2.55 $1,275
9 Jan 2015
14,606
17 Dec 2014 Curtis Ruegg
EVP and Technical Operations
Option 1,000 $2.55 $2,550
17 Dec 2014
15,106
9 Dec 2014 Curtis Ruegg
EVP and Technical Operations
Option 500 $2.55 $1,275
9 Dec 2014
14,606
18 Nov 2014 Curtis Ruegg
EVP and Technical Operations
Option 1,000 $2.55 $2,550
18 Nov 2014
15,106
28 Oct 2014 Curtis Ruegg
EVP and Technical Operations
Option 500 $2.55 $1,275
28 Oct 2014
13,768
17 Oct 2014 Curtis Ruegg
EVP and Technical Operations
Option 1,500 $2.55 $3,825
17 Oct 2014
14,768
17 Sep 2014 Curtis Ruegg
EVP and Technical Operations
Sale 2,000 $20.55 $41,100
17 Sep 2014
13,268


Revance Therapeutics Inc executives and stock owners

Revance Therapeutics Inc executives and other stock owners filed with the SEC include: